Round led by new investor V-Bio Ventures, with participation from existing investors Pontifax, Bpifrance, Kurma Partners, Hadean Ventures, Sunstone Life Science Ventures and Inserm Transfert Initiative
Financing follows recent progress of dencatistat into its third clinical programme, in essential thrombocythaemia, following lymphoma and solid tumours
Ward Capoen, Partner, V-Bio Ventures joins Step Pharma's Board of Directors
Saint-Genis-Pouilly, France, 15 October 2025, Step Pharma ("the Company"), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces the completion of a €38 million Series C financing round.
The Series C round was led by new investor V-Bio Ventures, a Ghent-based life sciences venture capital fund, with participation from existing investors Pontifax, Bpifrance, Kurma Partners, Hadean Ventures, Sunstone Life Science Ventures and Inserm Transfert Initiative.
The financing will enable Step Pharma to continue advancing its ‘pipeline in a product' strategy for dencatistat, a first-in-class, highly selective, orally bioavailable CTPS1 inhibitor currently in development for the treatment of cancers and blood disorders. All cancers appear to be highly reliant on CTPS1, a key component of the pyrimidine synthesis pathway, for DNA synthesis and cell proliferation.
Dencatistat is ...